scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJM199608083350604 |
P698 | PubMed publication ID | 8676932 |
P50 | author | A Clinton White | Q44838503 |
Donald N Forthal | Q89741676 | ||
P2093 | author name string | McCutchan JA | |
Kemper CA | |||
Bozzette SA | |||
Parenti DM | |||
Dubé MP | |||
Havlir DV | |||
Sattler FR | |||
Lavelle JP | |||
Dunne MW | |||
Witt MD | |||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | California | Q99 |
rifabutin | Q1135705 | ||
collaboration | Q1145523 | ||
azithromycin | Q165399 | ||
Mycobacterium avium avium | Q310728 | ||
P304 | page(s) | 392-398 | |
P577 | publication date | 1996-08-01 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group | |
P478 | volume | 335 |
Q73605437 | 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) |
Q35614631 | 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus |
Q44616568 | 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus |
Q74683288 | AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin |
Q28344776 | Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model |
Q35733945 | Antibiotic trials for coronary heart disease |
Q33659379 | Antiinfectives update: focus on treatment and prevention of viral and associated infections |
Q34115343 | Assessing the performance of a computer-based policy model of HIV and AIDS |
Q33978221 | Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients |
Q35302808 | Azithromycin for ocular toxoplasmosis |
Q46496257 | Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety |
Q36281588 | Bacterial infections in adult HIV-infected patients |
Q43801101 | Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes |
Q37883369 | Choosing the right macrolide antibiotic. A guide to selection |
Q33980683 | Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice |
Q73456232 | Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS |
Q33584119 | Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. |
Q50141101 | Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study |
Q28265322 | Current treatment of atypical mycobacteriosis |
Q22241907 | Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria |
Q41730934 | Discontinuing prophylaxis for opportunistic infection: guiding principles |
Q43787824 | Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000. |
Q35693261 | Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated? |
Q34727977 | Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV |
Q41331963 | Drug treatment of HIV-related opportunistic infections |
Q90497585 | Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality |
Q41690799 | Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group |
Q28379322 | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. |
Q54139769 | Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. |
Q34393599 | Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. |
Q40657726 | Fever of unknown origin in the HIV-infected patient: new scenario for an old problem |
Q91984625 | Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this? |
Q35818518 | Global strategies to prevent bacterial pneumonia in adults with HIV disease |
Q74404199 | Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients |
Q93501240 | HIV: prevention of opportunistic infections |
Q33850498 | HIV: primary and secondary prophylaxis for opportunistic infections |
Q45751850 | Human immunodeficiency virus infection, Part II. |
Q39100345 | Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician |
Q43599627 | Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease. |
Q37415433 | Improving outcomes in state AIDS drug assistance programs |
Q35558806 | Infections in Patients with Inherited Defects in Phagocytic Function |
Q41678925 | Innovative approaches to novel antibacterial drug discovery |
Q42762413 | Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection |
Q24197892 | Interventions for the prevention of mycobacterium avium complex in adults and children with HIV |
Q36311794 | Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? |
Q30779044 | Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group |
Q32039126 | Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients |
Q39226202 | Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report |
Q36170393 | Macrolides: A Canadian Infectious Disease Society position paper |
Q24679338 | Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society |
Q28343464 | Mefloquine is active in vitro and in vivo against Mycobacterium avium complex |
Q45081834 | Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease |
Q33977716 | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. |
Q54120812 | Mycobacteria as pathogens of respiratory infection. |
Q41336741 | Mycobacterial complications of HIV infection |
Q35874064 | Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy |
Q37202852 | Mycobacterium avium complex infection in HIV/AIDS patients |
Q34569262 | Nontuberculous mycobacteria immune reconstitution syndrome |
Q34949978 | Nontuberculous mycobacteria in the HIV infected patient |
Q35779935 | Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients |
Q30426863 | Nontuberculous mycobacterial infections |
Q42272342 | Nontuberculous mycobacterial infections in solid organ transplantation |
Q33851989 | Opportunistic infections and other clinical manifestations of HIV disease in children |
Q34305079 | Opportunistic infections in HIV disease: down but not out. |
Q37848432 | Oral azithromycin in extended dosage schedule for chronic, subclinical Chlamydia pneumoniae infection causing coronary artery disease: a probable cure in sight? Results of a controlled preliminary trial |
Q44766862 | Outpatient management of HIV-infected adults. The varied challenges for primary care |
Q41710621 | Overview of protease inhibitors. |
Q35692736 | Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections |
Q41615483 | Preventing and treating major opportunistic infections in AIDS. What's new and what's still true |
Q45752626 | Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals |
Q44255331 | Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. |
Q35677256 | Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]. |
Q41633522 | Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. |
Q35007043 | Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. |
Q33544612 | Prophylaxis against disseminated Mycobacterium avium complex in AIDS. |
Q34122368 | Prophylaxis of opportunistic infections. |
Q33936966 | Randomised trials of STD treatment for HIV prevention: report of an international workshop. HIV/STD Trials Workshop Group |
Q37876312 | Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial |
Q41633512 | Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. |
Q47829087 | Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. |
Q38786540 | Rifabutin: where do we stand in 2016? |
Q50883380 | Risk factors for rifampin mono-resistant tuberculosis. |
Q33717062 | Risk-benefit assessment of therapies for Mycobacterium avium complex infections |
Q33970989 | Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease |
Q71849403 | Severe neutropenia and prophylactic doses of rifabutin |
Q45001768 | Small Intestinal Infections |
Q41521259 | The Role of Advanced Generation Macrolides in the Prophylaxis and Treatment of Mycobacterium avium Complex (MAC) Infections |
Q53927453 | The effect of azithromycin on the pharmacokinetics of indinavir. |
Q34777454 | The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach |
Q41527229 | The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome |
Q44727844 | Therapeutic innovations for environmental mycobacteria |
Q37180338 | Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066) |
Q30951402 | Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia |
Q33982133 | Tolerance and pharmacokinetic interactions of rifabutin and azithromycin |
Q33691292 | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. |
Q74599772 | Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals |
Q41648609 | Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin |
Q41614452 | Tuberculosis and HIV infection: a review |
Q37865389 | Update of antibiotic trials for secondary prevention of coronary heart disease |
Q74775416 | [Disseminated infection with Mycobacterium avium complex (MAC) in HIV infection] |
Q77396620 | [HIV protease inhibitors: drug interactions] |
Q81643225 | [Respiratory infections caused by environmental mycobacteria] |
Search more.